Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

• Κύριοι συγγραφείς: Caixia Deng (Συγγραφέας), Hu Luo (Συγγραφέας), Xiangdong Zhou (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Open Journal of Cell and Protein Science - Peertechz Publications, 2018-10-01.
• Θέματα: Case Report
• Διαθέσιμο Online: Connect to this object online.

<p>So far, in the advanced non-small cell lung cancer (NSCLC) with clear epidermal growth factor receptor (EGFR) gene status, the treatment remmendations has reached an agreement: for patients with EGFR mutation-positive, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)...